U.S. markets closed

Asensus Surgical, Inc. (ASXC)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.9800+0.0300 (+1.54%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close1.9500
Open1.9500
Bid1.9800 x 1800
Ask2.0100 x 21500
Day's Range1.9100 - 2.0400
52 Week Range0.3200 - 6.9500
Volume11,687,950
Avg. Volume5,695,290
Market Cap463.962M
Beta (5Y Monthly)1.52
PE Ratio (TTM)N/A
EPS (TTM)-0.3710
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Asensus Surgical, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total sales are generated in the United States.
    Rating
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • Business Wire

    Asensus Surgical, Inc. to Participate in Three Upcoming Virtual Healthcare Conferences

    RESEARCH TRIANGLE PARK, N.C., September 08, 2021--Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will present at three upcoming virtual investor conferences:

  • Business Wire

    Asensus Surgical Receives FDA 510(k) Clearance for Expansion of Machine Vision Capabilities

    RESEARCH TRIANGLE PARK, N.C., September 01, 2021--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced that it has received 510(k) clearance from the FDA for an expansion of machine vision capabilities on the previously cleared Intelligent Surgical Unit™ (ISU™). The ISU is utilized with the Company’s SenhanceⓇ Surgical System which enables Digita

  • Business Wire

    Asensus Surgical, Inc. Reports Operating and Financial Results for the Second Quarter 2021

    RESEARCH TRIANGLE PARK, N.C., August 05, 2021--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the second quarter 2021.